Evidence map›Paper›PMID 40391771›Full record

ArticleOncotarget2025

Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells.

Shan Lu, Zhongyun Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shan LuDepartment of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Zhongyun DongDepartment of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Funding

Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cellsR21CA256009 · NCI · UNIVERSITY OF CINCINNATI · PI DONG, ZHONGYUN · 2022 to 2023
$413k
NCI NIH HHS R21 CA256009
6 · The paper itself

Abstract

We previously showed that proliferating cell nuclear antigen (PCNA) interacts with androgen receptor (AR) through a PIP-box (PIP-box4) at the N-terminus of AR and regulates AR activity. In this study, we further investigated PCNA/AR interaction. We identified a second PIP-box (PIP-box592) in the DNA binding domain of AR and found that dihydrotestosterone enhances the binding of full-length AR (AR-FL) but not a constitutively active variant (AR-V7) to PCNA. Treatment with R9-AR-PIP, a PIP-box4-mimicking small peptide, inhibits the PCNA/AR interaction, AR occupancy at the androgen response element (ARE) in

Indexed as

Proliferating Cell Nuclear AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSignal TransductionCell Line, TumorCell ProliferationDihydrotestosteroneGene Expression Regulation, NeoplasticHumansMaleProstate-Specific AntigenProtein BindingAR protein, humanDihydrotestosteronePCNA protein, humanProliferating Cell Nuclear AntigenProstate-Specific AntigenReceptors, Androgenandrogen receptorAR splicing variantsCRPCPCNAPCNA inhibitors

Identifiers

PMID40391771
PMCPMC12219270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.